e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Respiratory epidemiology: quality of life, therapy and socioeconomics
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Correlates of high levels of use of short-acting beta agonists in asthma
L. Laforest, J. Martin, I. Licaj, G. Devouassoux, G. Chatte, M. Broquet, E. Van Ganse (Lyon, Pierre Benite, Caluire, France)
Source:
Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics
Session:
Respiratory epidemiology: quality of life, therapy and socioeconomics
Session type:
Thematic Poster Session
Number:
4122
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Laforest, J. Martin, I. Licaj, G. Devouassoux, G. Chatte, M. Broquet, E. Van Ganse (Lyon, Pierre Benite, Caluire, France). Correlates of high levels of use of short-acting beta agonists in asthma. Eur Respir J 2011; 38: Suppl. 55, 4122
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Is there a problem with short-acting beta-2 agonist monotherapy in asthma?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020
What predicts short-acting beta agonist (SABA) monotherapy use in children?
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Polymorphism of β2-adrenergic receptor (β2-AR) and regular use of long-acting β-agonists in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
High use of SABAs is associated with higher exacerbation frequency
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001
Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 726s
Year: 2006
Use of partition tree to Identify genetic marker combination predicting bronchodilator response by inhaled short-acting beta 2 agonist
Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Year: 2011
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue?
Source: Annual Congress 2013 –Asthma and lung development: from genes to environment
Year: 2013
Abediterol, a novel long-acting inhaled beta
2
-agonist, has a fast association rate and long residence time at human beta
2
receptors
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD
Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation
Year: 2020
Long-acting β
2
-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept